CN114901664A - 吡啶酮化合物及应用 - Google Patents

吡啶酮化合物及应用 Download PDF

Info

Publication number
CN114901664A
CN114901664A CN202180007672.3A CN202180007672A CN114901664A CN 114901664 A CN114901664 A CN 114901664A CN 202180007672 A CN202180007672 A CN 202180007672A CN 114901664 A CN114901664 A CN 114901664A
Authority
CN
China
Prior art keywords
mol
reaction
compound
phenyl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202180007672.3A
Other languages
English (en)
Other versions
CN114901664B (zh
Inventor
李桢
唐锋
赵春艳
陈平
张国宝
唐任宏
任晋生
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Zaiming Pharmaceutical Co ltd
Original Assignee
Jiangsu Simcere Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Simcere Pharmaceutical Co Ltd filed Critical Jiangsu Simcere Pharmaceutical Co Ltd
Publication of CN114901664A publication Critical patent/CN114901664A/zh
Application granted granted Critical
Publication of CN114901664B publication Critical patent/CN114901664B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明提供了通式(A)所示化合物或其药学上可接受的盐、药物组合物及其制备方法，以及作为MAT2A抑制剂的用途。

Description

PCT国内申请，说明书已公开。

Claims (14)

  1. PCT国内申请，权利要求书已公开。
CN202180007672.3A 2020-01-10 2021-01-08 吡啶酮化合物及应用 Active CN114901664B (zh)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
CN202010026786 2020-01-10
CN202010026786X 2020-01-10
CN2020103623781 2020-04-30
CN202010362378 2020-04-30
CN202010658579 2020-07-09
CN2020106585796 2020-07-09
CN202010871227 2020-08-26
CN2020108712279 2020-08-26
CN2020109586038 2020-09-14
CN202010958603 2020-09-14
PCT/CN2021/070887 WO2021139775A1 (zh) 2020-01-10 2021-01-08 吡啶酮化合物及应用

Publications (2)

Publication Number Publication Date
CN114901664A true CN114901664A (zh) 2022-08-12
CN114901664B CN114901664B (zh) 2024-07-02

Family

ID=76787754

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180007672.3A Active CN114901664B (zh) 2020-01-10 2021-01-08 吡啶酮化合物及应用

Country Status (2)

Country Link
CN (1) CN114901664B (zh)
WO (1) WO2021139775A1 (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022052924A1 (zh) * 2020-09-11 2022-03-17 上海凌达生物医药有限公司 一类含氮稠环类化合物的制备方法和用途
EP4273146A1 (en) 2020-12-31 2023-11-08 Nanjing Zaiming Pharmaceutical Co., Ltd. Tricyclic compound and use thereof
WO2022206730A1 (zh) * 2021-03-29 2022-10-06 武汉人福创新药物研发中心有限公司 嘧啶并吡嗪酮化合物及其用途
AU2022373595A1 (en) 2021-10-20 2024-05-02 Insilico Medicine Ip Limited Methionine adenosyltransferase 2a (mat2a) inhibitors and uses thereof
WO2023116696A1 (zh) * 2021-12-21 2023-06-29 南京正大天晴制药有限公司 蛋氨酸腺苷转移酶2a的杂环抑制剂
WO2023169554A1 (zh) * 2022-03-11 2023-09-14 赛诺哈勃药业（成都）有限公司 甲硫氨酸腺苷转移酶抑制剂、其制备方法及应用
CN117003734A (zh) * 2022-04-27 2023-11-07 浙江海正药业股份有限公司 嘧啶并环类衍生物及其制备方法和用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101573358A (zh) * 2006-09-15 2009-11-04 辉瑞产品公司 吡啶并(2,3-d)嘧啶酮化合物及其作为pi3抑制剂的用途
WO2010039740A1 (en) * 2008-09-30 2010-04-08 Exelixis, Inc. PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα AND MTOR
CN103012399A (zh) * 2012-11-22 2013-04-03 中国科学院广州生物医药与健康研究院 7-氧代吡啶并嘧啶类化合物及其药用组合物和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105330699B (zh) * 2014-08-13 2018-12-04 山东汇睿迪生物技术有限公司 一种含磷吡啶并[2,3-d]嘧啶-7-酮类化合物或其药学上可接受的盐、药物组合物及其应用
MX2019002303A (es) * 2016-08-31 2019-07-15 Agios Pharmaceuticals Inc Inhibidores de procesos metabolicos celulares.
WO2018039972A1 (en) * 2016-08-31 2018-03-08 Agios Pharmaceuticals, Inc. Inhibitors of cellular metabolic processes
CN110914267B (zh) * 2017-07-19 2022-07-12 江苏奥赛康药业有限公司 嘧啶并吡啶酮或者吡啶并吡啶酮类化合物及其应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101573358A (zh) * 2006-09-15 2009-11-04 辉瑞产品公司 吡啶并(2,3-d)嘧啶酮化合物及其作为pi3抑制剂的用途
WO2010039740A1 (en) * 2008-09-30 2010-04-08 Exelixis, Inc. PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα AND MTOR
CN103012399A (zh) * 2012-11-22 2013-04-03 中国科学院广州生物医药与健康研究院 7-氧代吡啶并嘧啶类化合物及其药用组合物和应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JIAYI SHEN 等: "Structure-Based Design of 5‑Methylpyrimidopyridone Derivatives as New Wild-Type Sparing Inhibitors of the Epidermal Growth Factor Receptor Triple Mutant (EGFRL858R/T790M/C797S)", 《J. MED. CHEM.》 *

Also Published As

Publication number Publication date
CN114901664B (zh) 2024-07-02
WO2021139775A1 (zh) 2021-07-15

Similar Documents

Publication Publication Date Title
CN114901664A (zh) 吡啶酮化合物及应用
TWI719437B (zh) Mat2a之雜雙環抑制劑及治療癌症之使用方法
KR102429419B1 (ko) Rho-키나아제 억제제로서 티로신 아마이드 유도체
JP6802251B2 (ja) 癌の処置のためのｄｕｂ阻害剤としてのシアノピロリジン
CN114394966A (zh) 吡啶并嘧啶酮cdk2/4/6抑制剂
CN112055709A (zh) 吡嗪化合物和其用途
US11319303B2 (en) Compound used as autophagy regulator, and preparation method therefor and uses thereof
TWI785474B (zh) 用作選擇性Aurora A抑制劑的新型雜環化合物
CN104837829A (zh) 抑制剂化合物
CN110655503A (zh) 取代的三唑类化合物、包含其的药物组合物、其制备方法及其用途
CN112955432B (zh) 稠合芳香环类衍生物、其制备方法及其在医药上的应用
US10239873B2 (en) 7-azaindole or 4,7-diazaindole derivatives as IKKϵ epsilon and TBK1 inhibitor and pharmaceutical composition comprising same
BR112016028845B1 (pt) Composto, composição farmacêutica e uso de um composto
US10793575B2 (en) Oxoisoquinoline derivatives
CN110520416B (zh) 多取代吡啶酮类衍生物、其制备方法及其医药用途
WO2020215998A1 (zh) 嘧啶并五元杂环类化合物及其作为突变型idh2抑制剂的用途
TWI705965B (zh) 新穎三環化合物
CN114885607B (zh) 喹啉基膦氧化合物及其组合物和用途
AU2017323112B2 (en) Pyrido five-element aromatic ring compound, preparation method therefor and use thereof
CN112300173B (zh) 一类含氮多环类化合物、制备方法和用途
CN115960098A (zh) 一类含氮稠环类化合物的制备方法和用途
CN111057048B (zh) 一类氨基吡嗪/吡啶类化合物、制备方法和用途
CN112279837B (zh) 吡嗪化合物和其用途
CN111747954B (zh) 吡嗪化合物和其用途
CN112778336A (zh) 一类含氮稠环类sting调节剂类化合物、制备方法和用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20230807

Address after: 210032 No.99, Huakang Road, Jiangbei new district, Nanjing City, Jiangsu Province

Applicant after: Nanjing Zaiming Pharmaceutical Co.,Ltd.

Address before: 210042 699 Xuanwu Road, Xuanwu District, Nanjing, Jiangsu -18

Applicant before: JIANGSU SIMCERE PHARMACEUTICAL Co.,Ltd.

GR01 Patent grant